obstacles, the main technical issue with DC vaccines that needed to be overcome in order to make it a feasible translational avenue was the limited source material due to the low prevalence of DCs in the peripheral blood, ranging from 0.1–1% of peripheral blood mononuclear cells (PBMC) [41]...
from PBMCs for improved adhesion and differentiation into macrophages. Here they presented Cellstar®as the metfhod of choice in combination with RPMI medium. However, this does not concern the differentiation to osteoclasts and their resorption capacity, which were not subject of their study [26...